Rafael Amado - Dec 30, 2024 Form 4 Insider Report for Zai Lab Ltd (ZLAB)

Role
President, Head of Global Oncology Research and Development
Signature
/s/ Bruce Blefeld, Attorney-in-Fact
Stock symbol
ZLAB
Transactions as of
Dec 30, 2024
Transactions value $
-$199,289
Form type
4
Date filed
1/2/2025, 04:13 PM
Previous filing
Aug 14, 2024
Next filing
Jan 8, 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ZLAB American Depositary Shares Options Exercise +21K +102.86% 41.4K Dec 30, 2024 Direct F1, F2, F3
transaction ZLAB American Depositary Shares Sale -$199K -7.58K -18.31% $26.28 33.8K Dec 31, 2024 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ZLAB Restricted Share Units Options Exercise $0 -21K -25% $0.00 63K Dec 30, 2024 American Depositary Shares 21K Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each American Depositary Share (ADS) represents ten Ordinary Shares of the issuer. Our ADSs and Ordinary Shares are fully fungible. For purposes of this Form 4, we are reporting this in terms of ADSs.
F2 ADSs acquired upon vesting of Restricted Share Units ("RSUs").
F3 Each RSU represents a contingent right to receive one ADS.
F4 These ADSs were sold automatically to cover taxes upon vesting of RSUs.
F5 These RSUs vest in equal annual installments over five years beginning on 12/30/2023, the first anniversary of the date of grant. Vested shares will be delivered to the reporting person following vesting.

Remarks:

President, Head of Global Oncology Research and Development